Compression-coated pulsatile chronomodulated therapeutic system: QbD assisted optimization

• Published in: Drug delivery Vol. 29; no. 1; pp. 2258 - 2268
• Main Authors: Aldawsari, Hibah M., Naveen, N. Raghavendra, Alhakamy, Nabil A., Goudanavar, Prakash S., Rao, GSN Koteswara, Budha, Roja Rani, Nair, Anroop B., Badr-Eldin, Shaimaa M.
• Format: Journal Article
• Language: English
• Published: Philadelphia Taylor & Francis 31.12.2022; Taylor & Francis Ltd; Taylor & Francis Group
• Subjects: chronobiology; Circadian rhythm; Compression coating; Drug delivery systems; Drug dosages; Eudragit RLPO; Hydrogels; ketorolac tromethamine; Optimization; PEO WSR coagulant; Pharmaceutical sciences; Pharmacy; quality by design; Rheumatoid arthritis; Variables
• ISSN: 1071-7544; 1521-0464
• DOI: 10.1080/10717544.2022.2094500

Pulsatile drug delivery systems have drawn attention in contemporary research for designing chronotherapeutic systems. The current work aims to design pulsatile ketorolac tromethamine tablets using compression coating for delayed delivery with a lag time suitable for the treatment of morning stiffness in arthritis. Rapidly disintegrating core tablets of ketorolac tromethamine were formulated using super-disintegrants, and the optimized formulation was compression using PEO WSR coagulant and Eudragit RLPO for delaying the release. The central composite design and response surface methodology were employed to optimize the formulation and process parameters namely PEO WSR Coagulant (X 1 ), Eudragit RLPO (X 2 ), and Hardness (X 3 ). The dependent variables optimized were lag time and time required for 95% drug release. Analysis using response surface graphs and mathematical modeling of the results allowed identifying and quantifying the formulation variables active on the selected responses. A polynomial equation fitted to the data was used to predict the composition with optimum responses. Compression-coated pulsatile tablets' optimized composition exhibited a lag time of 9 h and released 95% of the ketorolac tromethamine in 17.42 h. Validation of the mathematical model assured the reliability of QBD in formulation design. In vivo X-ray imaging and pharmacokinetic studies established a strong relationship between the coated polymers maintaining the desired lag time for delayed delivery of the active to coincide with the chronobiology for enhanced bioavailability at the right time when needed.